With the 2025 regulatory deadlines now firmly established as the baseline, 2026 represents a shift from compliance to system-level optimization. For organizations developing and manufacturing injectable and parenteral drug products, particularly advanced and difficult-to-inspect therapies, the expectation is no longer that data meets compendial requirements, but that it can hold up under regulatory scrutiny.
At Gateway Analytical, container integrity and particulate control are treated as governance-led strategies. We focus on the intersection of formulation complexity, primary container behavior, and inspection limitations to ensure that the container closure system strengthens the regulatory narrative rather than introducing residual risk.
As we move into 2026, we are excited to partner with your biotech, pharmaceutical, and quality-driven CDMO team to deliver:
Proactive System Qualification
Applying USP <661.1> and <661.2> to establish an early, high-resolution understanding of material safety, compatibility, and extractables control, particularly for non-standard formulations and high-risk modalities.
Deterministic CCIT
Embedding high-sensitivity, deterministic leak detection early in development to replace probabilistic assumptions with quantitative assurance. Reducing downstream investigation burden, and accelerating development and timelines.
System-Level Functional and Inspection
Executing USP <382> suitability testing alongside difficult-to-inspect product strategies to ensure that parenteral, inhalation, and ophthalmic delivery systems perform reliably, not only in the lab, but in real-world patient use and under inspection challenge.
Are you confident your container integrity and particulate data will stand up under inspection? Reach out today for a priority consultation: 📞 (724) 443-1900 | ✉️ in**@***************al.com
